PKM and hepatocellular carcinoma: Although, we did not provide a direct demonstration for the inhibition of PKM2 nuclear translocation, this event might play a role in the anti-tumor activity of the drug combination, as suggested by previous findings showing that sorafenib-mediated dephosphorylation of PKM2Tyr105 is critical for the sensitivity to this drug in HCC cells (80).